Baseline Demographics, Clinical Characteristics, Treatment Patterns, and Burden of Atopic Dermatitis in Patients Initiating Dupilumab: A Retrospective, Observational Study Using Data From a Real‐World Registry (CORNERSTONE)

Background Chinese atopic dermatitis (AD) patients initiating dupilumab in real‐world settings are not well characterized. Objective To describe baseline characteristics of Chinese AD patients starting dupilumab. Methods This was a retrospective study utilizing real‐world data from the observational registry of China Type 2 Inflammatory Skin Diseases, CORNERSTONE, for AD patients initiating dupilumab. Results Between August 2021 and July 2022, 3960 dupilumab users were identified (age: 1–96 years, male: 58.5%). Early‐onset AD was noted in 13.2%, with common anatomic sites affected being the trunk, arm, and leg. Clinical phenotypes included typical flexural dermatitis (62.1%), inflammatory (20.2%), and xerosis (15.2%). Type 2 inflammatory comorbidities were present in 50.8%, with allergic rhinitis/sinusitis, food allergy, and bronchial asthma being most prevalent. Topical corticosteroids and antihistamines often precede and accompany dupilumab. Mean Eczema Area and Severity Index (EASI) score was 13.5, Body Surface Area (BSA) affected 29.7%, and Peak Pruritus Numerical Rating Scale (PP‐NRS) 7.2. Infants’ Dermatitis Quality of Life index (IDQoL), Children’s Dermatology Life Quality Index (CDLQI), and Dermatology Life Quality Index (DLQI) scores were 16.9, 13.8, and 13.1 for patients < 4, ≥ 4–< 16, and ≥ 16 years, respectively. Conclusions In China, real‐world AD patients initiating dupilumab exhibit a broad age spectrum and clinical characteristics, with multidimensional baseline disease burden.